Delta-9-Tetrahydrocannabinol-Induced Dopamine Release as a Function of Psychosis Risk: 18F-Fallypride Positron Emission Tomography Study

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Kuepper, Rebecca ^a   Ceccarini, Jenny ^c   Lataster, Johan ^a,d   van Os, Jim ^a,e   van Kroonenburgh, Marinus ^f   van Gerven, Joop M A ^g   Marcelis, Machteld ^a   van Laere, Koen ^c   Henquet, Cécile ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b PsyQ Heerlen Mondriaan ^*  (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d OPEN UNIVERSITY OF THE NETHERLANDS   (Netherlands)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DRONABINOL; FALLYPRIDE FLUORINE F 18; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; FEMALE; FIRST DEGREE RELATIVE; GENETIC RISK; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; LIGAND BINDING; MALE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN INDUCTION; PSYCHOSIS;

ADMINISTRATION, INHALATION; ADULT; BENZAMIDES; CAUDATE NUCLEUS; DOPAMINE; DRONABINOL; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PSYCHOTIC DISORDERS; PYRROLIDINES; RADIOPHARMACEUTICALS; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 84880810573     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070378     Document Type: Article

References (51)

1. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, et al. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370: 319-328.
2. Zammit S, Moore TH, Lingford-Hughes A, Barnes TR, Jones PB, et al. (2008) Effects of cannabis use on outcomes of psychotic disorders: systematic review. British Journal of Psychiatry 193: 357-363.
3. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57: 594-608.
4. Henquet C, van Os J, Kuepper R, Delespaul P, Smits M, et al. (2010) Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry 196: 447-453.
5. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, et al. (2005) Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 330: 11.
6. G.R.O.U.P (2011) Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. Archives of General Psychiatry 68: 138-147.
7. Barkus EJ, Stirling J, Hopkins RS, Lewis S, (2006) Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39: 175-178.
8. Barkus E, Lewis S, (2008) Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychological Medicine 38: 1267-1276.
9. Kuepper R, Morrison PD, van Os J, Murray RM, Kenis G, et al. (2010) Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr Res 121: 107-117.
10. Arnone D, Barrick TR, Chengappa S, Mackay CE, Clark CA, et al. (2008) Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuroimage 41: 1067-1074.
11. Matochik JA, Eldreth DA, Cadet JL, Bolla KI, (2005) Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend 77: 23-30.
12. Yucel M, Solowij N, Respondek C, Whittle S, Fornito A, et al. (2008) Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 65: 694-701.
13. Pertwee RG, (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
14. Wilson RI, Nicoll RA, (2002) Endocannabinoid signaling in the brain. Science 296: 678-682.
15. Howes OD, Kapur S, (2009) The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophrenia Bulletin 35: 549-562.
16. Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, et al. (2002) Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 948: 155-158.
17. Tanda G, Pontieri FE, Di Chiara G, (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276: 2048-2050.
18. Voruganti LNP, Slomka P, Zabel P, Mattar A, Awad AG, (2001) Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Research: Neuroimaging 107: 173-177.
19. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, et al. (2009) Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 34: 759-766.
20. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM, (2009) Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage 48: 186-190.
21. Barkus E, Morrison PD, Vuletic D, Dickson JC, Ell PJ, et al. (2011) Does intravenous Delta9-tetrahydrocannabinol increase dopamine release? A SPET study. Journal of psychopharmacology 25: 1462-1468.
22. Wechsler D (2000) WAIS-III Nederlandstalige bewerking. Afnames en scoringshandleiding. Lisse: Swets Test Publishers.
23. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. Washington, D.C.: Author.
24. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, et al. (2006) Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend 85: 114-122.
25. McGuffin P, Farmer A, Harvey I, (1991) A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Archives of General Psychiatry 48: 764-770.
26. Kay SR, Opler LA, Lindenmayer JP, (1989) The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. British Journal of Psychiatry 155: 59-67.
27. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, et al. (1988) The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Archives of General Psychiatry 45: 1069-1077.
28. Spitzer RL, Williams JB, Gibbon M, First MB, (1992) The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 49: 624-629.
29. Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, et al. (2008) Effect of intrapulmonary tetrahydrocannabinol administration in humans. Journal of psychopharmacology 22: 707-716.
30. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R, (2006) Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 95: 1308-1317.
31. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, et al. (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88: 82-88.
32. Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, et al. (2002) Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 46: 170-188.
33. Mukherjee J, Yang ZY, Brown T, Lew R, Wernick M, et al. (1999) Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol 26: 519-527.
34. Christian BT, Lehrer DS, Shi B, Narayanan TK, Strohmeyer PS, et al. (2006) Measuring dopamine neuromodulation in the thalamus: using [F-18]fallypride PET to study dopamine release during a spatial attention task. Neuroimage 31: 139-152.
35. Lataster J, Collip D, Ceccarini J, Haas D, Booij L, et al. (2011) Psychosocial stress is associated with in vivo dopamine release in human ventromedial prefrontal cortex: a positron emission tomography study using [(1)F]fallypride. Neuroimage 58: 1081-1089.
36. Vrieze E, Ceccarini J, Pizzagalli DA, Bormans G, Vandenbulcke M, et al. (2013) Measuring extrastriatal dopamine release during a reward learning task. Human brain mapping 34: 575-586.
37. Ceccarini J, Vrieze E, Koole M, Muylle T, Bormans G, et al. (2012) Optimized in vivo detection of dopamine release using 18F-fallypride PET. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 53: 1565-1572.
38. Alpert NM, Badgaiyan RD, Livni E, Fischman AJ, (2003) A novel method for noninvasive detection of neuromodulatory changes in specific neurotransmitter systems. Neuroimage 19: 1049-1060.
39. Lammertsma AA, Hume SP, (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158.
40. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ, (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6: 279-287.
41. Talairach J, Tournoux P (1988) Co-planar Stereotaxic Atlas of the Human Brain. New York: Thieme.
42. Overall J, Gorham D, (1988) The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacology Bulletin 24: 97-99.
43. Kuepper R, Skinbjerg M, Abi-Dargham A, (2012) The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. Handb Exp Pharmacol 212: 1-26.
44. Morrison PD, Murray RM, (2009) From real-world events to psychosis: the emerging neuropharmacology of delusions. Schizophrenia Bulletin 35: 668-674.
45. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, et al. (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29: 2108-2114.
46. Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, et al. (2009) Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 194: 371-372.
47. Wong DF, Kuwabara H, Horti AG, Raymont V, Brasic J, et al. (2010) Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 52: 1505-1513.
48. Mathew RJ, Wilson WH, Coleman RE, Turkington TG, DeGrado TR, (1997) Marijuana intoxication and brain activation in marijuana smokers. Life sciences 60: 2075-2089.
49. Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, Wiethe KE, (1992) Regional cerebral blood flow after marijuana smoking. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 12: 750-758.
50. O'Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, et al. (2002) Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 26: 802-816.
51. Pappata S, Dehaene S, Poline JB, Gregoire MC, Jobert A, et al. (2002) In vivo detection of striatal dopamine release during reward: a PET study with [(11)C]raclopride and a single dynamic scan approach. NeuroImage 16: 1015-1027.